Interferon β for Multiple Sclerosis.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) management benefits from diverse disease-modifying therapies.
• Interferon beta (IFN-β) remains a relevant treatment option despite newer alternatives.
• Understanding IFN-β's role is crucial for clinical decision-making in MS.

Purpose of the Study:

• To review the mechanism of action of interferon beta (IFN-β) in multiple sclerosis.
• To summarize the safety profile and efficacy of IFN-β for relapsing-remitting MS and clinically isolated syndromes.
• To evaluate the evidence for IFN-β use in secondary progressive MS.

Main Methods:

• Literature review of existing studies on interferon beta (IFN-β).
• Analysis of data on short-term and long-term efficacy.
• Assessment of safety and tolerability data.

Main Results:

• Interferon beta (IFN-β) has a defined mechanism of action relevant to MS.
• IFN-β demonstrates significant short- and long-term efficacy in relapsing-remitting MS and CIS.
• Overall safety and tolerability are well-characterized.
• Limited evidence supports clear benefit in secondary progressive MS.

Conclusions:

• Interferon beta (IFN-β) remains an important therapeutic option for specific multiple sclerosis subtypes.
• Its established safety and efficacy profile supports its continued use in relapsing forms of MS.
• Further research may clarify its role in progressive MS.